Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Scheduled Outpatient Red Blood Cell Exchange Program Reduces Admission and Complications in Sickle Cell Disease

Naresh Bumma, MD, Andrew Kin, MD, Malini Surapaneni, MD, Seongho Kim, PhD, Paul Swerdlow, MD

Blood (2017) 130 (Supplement 1): 3536.

https://doi.org/10.1182/blood.V130.Suppl_1.3536.3536

Published: 2017

Journal Articles

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

Kenneth I. Ataga, Wally R. Smith, Laura M. De Castro, Paul Swerdlow, Yogen Saunthararajah, Oswaldo Castro, Elliot Vichinsky, Abdullah Kutlar, Eugene P. Orringer, Greg C. Rigdon, Jonathan W. Stocker

Blood (2008) 111 (8): 3991–3997.

https://doi.org/10.1182/blood-2007-08-110098

Published: 2008

Includes: Supplemental data

Journal Articles

The Landscape of Thrombophilia in Sickling Disorders: Unfamiliar Terrain.

Lisabette Littsey, RN, MSN, Andrea S. Haggood, RN, MSN, Paul Swerdlow, MD, Judith C. Andersen, MD

Blood (2007) 110 (11): 3810.

https://doi.org/10.1182/blood.V110.11.3810.3810

Published: 2007

Journal Articles

Beneficial Effect of Zinc Supplementation on Oxidative Stress, Cytokines, and NF-κB DNA Binding in Sickle Cell Disease Patients.

Bin Bao, PhD, Ananda Prasad, MD, Ph.D, Frances W.J. Beck, Ph.D., Paul Swerdlow, MD, Anupam Suneja, MD

Blood (2006) 108 (11): 1203.

https://doi.org/10.1182/blood.V108.11.1203.1203

Published: 2006

Journal Articles

A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.

Paul Swerdlow, MD, Kenneth Ataga, MD, Wally Smith, MD, Yogen Saunthararajah, MD, Jonathan W. Stocker, PhD

Blood (2006) 108 (11): 685.

https://doi.org/10.1182/blood.V108.11.685.685

Published: 2006

Journal Articles

Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.

Kenneth I. Ataga, MBBS, Laura M. DeCastro, MD, Paul Swerdlow, MD, Yogen Saunthararajah, MD, Wally Smith, MD, The ICA-17043 Study Investigators6

Blood (2004) 104 (11): 103.

https://doi.org/10.1182/blood.V104.11.103.103

Published: 2004

NARROW

Scheduled Outpatient Red Blood Cell Exchange Program Reduces Admission and Complications in Sickle Cell Disease

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

The Landscape of Thrombophilia in Sickling Disorders: Unfamiliar Terrain.

Beneficial Effect of Zinc Supplementation on Oxidative Stress, Cytokines, and NF-κB DNA Binding in Sickle Cell Disease Patients.

A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.

Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.

Email alerts

ASH Publications

American Society of Hematology

Scheduled Outpatient Red Blood Cell Exchange Program Reduces Admission and Complications in Sickle Cell Disease

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

The Landscape of Thrombophilia in Sickling Disorders: Unfamiliar Terrain.

Beneficial Effect of Zinc Supplementation on Oxidative Stress, Cytokines, and NF-κB DNA Binding in Sickle Cell Disease Patients.

A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.

Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only